Abstract:Recent developments in tumor immunology and biotechnology have made cancer gene therapy and immunotherapy feasible. The current efforts for cancer gene therapy mainly focus on using immunogenes, chemogenes and tumor suppressor genes. Central to all these therapies is the development of efficient vectors for gene therapy. By far, adenovirus (AdV)-mediated gene therapy is one of the most promising approaches, as has confirmed by studies relating to animal tumor models and clinical trials. Dendritic cells (DCs) are highly efficient, specialized antigen-presenting cells, and DC-based tumor vaccines are regarded as having much potential in cancer immunotherapy. Vaccination with DCs pulsed with tumor peptides, lysates, or RNA, or loaded with apoptotic/necrotic tumor cells, or engineered to express certain cytokines or chemokines could induce significant antitumor cytotoxic T lymphocyte (CTL) responses and antitumor immunity. Although both AdV-mediated gene therapy and DC vaccine can both stimulate antitumor immune responses, their therapeutic efficiency has been limited to generation of prophylactic antitumor immunity against re-challenge with the parental tumor cells or to growth inhibition of small tumors. However, this approach has been unsuccessful in combating well-established tumors in animal models. Therefore, a major strategic goal of current cancer immunotherapy has become the development of novel therapeutic strategies that can combat well-established tumors, thus resembling real clinical practice since a good proportion of cancer patients generally present with significant disease. In this paper, we review the recent progress in AdV-mediated cancer gene therapy and DC-based cancer vaccines, and discuss combined immunotherapy including gene therapy and DC vaccines. We underscore the fact that combined therapy may have some advantages in combating well-established tumors vis-a-vis either modality administered as a monotherapy.

705. A New Strategy for Cancer Therapy: Application of Adenovirus-Mediated Complete-Length Antibody Gene

Gene Therapy Using Adenovirus-Mediated Full-Length Anti-Her-2 Antibody For Her-2 Overexpression Cancers

271. Full-Length Antibody Therapy Mediated by Adenovirus in Rodent and Non-Primate Animal Models

Effective gene-viral therapy of leukemia by a new fiber chimeric oncolytic adenovirus expressing TRAIL: in vitro and in vivo evaluation.

Cancer Gene Therapy of Adenovirus-Mediated Anti-4-1bb Scfv in Immunocompetent Mice

Effective Inhibition Of Cancer Cells By Recombinant Adenovirus Expressing Egfr-Targeting Artificial Microrna And Reversed-Caspase-3

Combinational Adenovirus-Mediated Gene Therapy and Dendritic Cell Vaccine in Combating Well-Established Tumors

Utilizing Adenovirus Knob Proteins as Carriers in Cancer Gene Therapy Amidst the Presence of Anti-Knob Antibodies

Progress in systemic administration of adenovirus vector for cancer gene therapy

Adenoviral gene therapy for cancer: from vectors to targeted and replication competent agents (review).

Co-application of Ricin A Chain and a Recombinant Adenovirus Expressing Ricin B Chain As a Novel Approach for Cancer Therapy

[Gene Expression of Tumor Cells Both in Vitro and in Vivo Enhanced by Integrin-Targeting Adenovirus Vector].

Recent Developments in the Use of Adenoviruses and Immunotoxins in Cancer Gene Therapy

Combination of Adenovirus and Cross-Linked Low Molecular Weight PEI Improves Efficiency of Gene Transduction.

“Double-punch” strategy for delivery of viral immunotherapy with prolonged tumor retention and enhanced transfection efficacy

Effective Gene-Viral Therapy For Telomerase-Positive Cancers By Selective Replicative-Competent Adenovirus Combining With Endostatin Gene

[Advances in research on oncolytic adenoviruses in tumor therapy]

Oncolytic Adenovirus Programmed by Synthetic Gene Circuit for Cancer Immunotherapy

The Study of Adenovirus Mediated Biospecific Antibody Fusion Protein Targeting to EGFR and HER2

Targeting Tumor Neoangiogenesis via Targeted Adenoviral Vector to Achieve Effective Cancer Gene Therapy for Disseminated Neoplastic Disease

Recent advances in genetic modification of adenovirus vectors for cancer treatment